Together, the ER, PR, and HER2 status form the foundation for treatment decisions in modern breast cancer management, with additional biomarkers like BRCA1/2 mutations and PD-1 further informing therapeutic strategies (12–16). Here, ERBB2 is linked to breast cancer.